BVF Related Analyst Ratings
-
Goldman Sachs Raises Price Targets for Healthcare Services; Upgrades ABC, Downgrades PSSI
-
J.P. Morgan Initiates Coverage on Biovail (BVF) with an Overweight
-
Credit Suisse Upgrades Biovail (BVF) to Outperform
-
TD Newcrest Upgrades Biovail (BVF) to Action List Buy
-
Deutsche Bank Upgrades Biovail (BVF) to Buy; Valuation Compelling
-
Goldman Sachs Upgrades Biovail Corporation (BVF) to Neutral
-
Goldman Sachs Downgrades Biovail (BVF) to Sell
-
UBS Initiates Coverage on Several Drug Manufacturers
-
BMO Upgrades Biovail (BVF) to Outperform
-
Canaccord Starts Biovail (BVF) at Buy; $14 PT
-
Paradigm Downgrades Biovail (BVF) to Hold
-
CIBC Downgrades Biovail (BVF) to Sector Underperform
-
CIBC Downgrades Biovail (BVF) to Sector Perform
-
BMO Cuts PT on Biovail (BVF) from $15.75 to $13.50
-
S&P Equity Research Downgrades Biovail (BVF) to Strong Sell
-
BMO Capital Upgrades Biovail (BVF) to Market Perform
-
Biovail (BVF): Actionable call alert!
-
Goldman Sachs downgrades Biovail (BVF) to Neutral
-
Credit Suisse downgrades Biovail (BVF) to Neutral
-
Goldman Sachs Starts Biovail (BVF) at Buy
-
BMO Securities Upgrades Biovail (BVF) to Outperform
-
Citigroup upgrades Biovail Corp (BVF) to Hold
-
Credit Suisse Initiates Coverage on Specialty Pharmaceuticals
-
Biovail (BVF) July option implied volatility at 50 into Summary Judgment
-
Rackable Systems (RACK) Lower on Cautious Analyst Report
-
Merrill Lynch downgrades Biovail (BVF) to Neutral
-
Citigroup downgrades BVF to Sell
-
Morgan Stanley upgrades BVF to Overweight
-
Merrill Lynch Upgrades BVF
-
BMO Nesbitt Upgrades BVF
-
Susquehanna Started BVF at Neutral
Back to BVF Stock Lookup
